Biotechnology
I-Mab and ABL Bio to Present Preclinical Data for Joint Bispecific Antibody Program at the 2020 American Association for Cancer Research Virtual Meeting II
SHANGHAI and GAITHERSBURG, Md., June 12, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, will be presenting preclinical data on a newly developed, novel asset TJ...
2020-06-12 20:00
7042
World's first iLDC enabling ADC drug receives IND clearance by the US FDA
SUZHOU, China, June 11, 2020 /PRNewswire/ -- GeneQuantum Healthcare (GQ) has recently received the US IND approval for its in-house developed next generation antibody drug conjugate (ADC) asset, GQ1001. This isthe world's first site-specific ADC produced using the intelligent ligase-dependent co...
2020-06-11 17:10
1125
ChemPartner Makes Additional Investments in Biologics from Research to Manufacturing Capabilities
SHANGHAI, June 10, 2020 /PRNewswire/ -- Shanghai ChemPartner announced the additional investments the company is making into its biologics business unit to further its capabilities and capacity in biologics discovery through development and manufacturing. "ChemPartner has rich experience in prov...
2020-06-10 23:03
1395
CellResearch Corporation - Source of cGMP Umbilical Cord Lining Stem Cells for COVID-19 Related Investigator Initiated Clinical Trials
SINGAPORE, June 10, 2020 /PRNewswire/ -- CellResearch Corporation (CellResearch), a regenerative medicine biotechnology company, is making its cGMP-grade umbilical cord lining stem cell product, CorLiCyte®, available complimentary to any licensed medical institution that is seeking to initiat...
2020-06-10 21:00
1012
Collaborating in Innovative Medical R&D to combat the pandemic, Alphamab Oncology and Institut Pasteur Shanghai Announce Partnership to Co-develop COVID-19 Neutralizing Antibody
SUZHOU, China, June 9, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) announced that Jiangsu Alphamab Biopharmaceuticals Co., Ltd. ("Jiangsu Alphamab"), a wholly-owned subsidiary of the Company, has entered a partnership agreement with Institut Pasteur ofShanghai, Chinese Academy of...
2020-06-10 08:40
5855
Alphamab Oncology and Sanofi Enter Collaboration on KN026 in HER2+ Breast Cancer
SUZHOU, China, June 8, 2020 /PRNewswire/ -- Alphamab Oncology (stock code: 9966 HK) a clinical stage biopharmaceutical company focusing on innovative biologics medicine for oncology, and Sanofi (EURONEXT: SAN and NASDAQ: SNY), a global biopharmaceutical leader, announced today that Jiangsu Alpham...
2020-06-09 10:10
5766
Innovent and Roche Enter into A Strategic Collaboration to Discover and Develop Multiple Products including Cellular Therapies and Bispecific Antibodies
SUZHOU, China, June 8, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announ...
2020-06-09 07:30
1788
Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer
SHANGHAI and HONG KONG, June 8, 2020 /PRNewswire/ -- Antengene Corporation
(Antengene) today announced its appointment of Mr.Donald Lung as Chief
Financial Officer (CFO), effectiveJune 8, 2020. Donald will report directly to
Dr.Jay Mei, Chairman and CEO of Antengene.
2020-06-08 20:00
2185
Samsung Biologics Unveils Virtual Exhibition Hall to Digitally Connect with Clients at BIO 2020
SONGDO, South Korea, June 8, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) announced the launch of a Virtual Exhibition Hall, coinciding with the opening of BIO Digital 2020 week. As the biopharmaceutical industry's largest event, BIO International Convention brings together over 17,000 indu...
2020-06-08 19:00
1743
Healios Successfully Establishes Proprietary Universal Donor Cell Research Line
TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593),Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are next-generation iPS cells created with gene-editing technology to engineer a low risk of immune r...
2020-06-05 13:00
2103
PharmAbcine signs a license agreement with Wincal Biopharm to expand indications of PharmAbcine's existing assets to non-oncology areas
DAEJEON, South Korea, June 3, 2020 /PRNewswire/ -- PharmAbcine (KOSDAQ: 208340), a clinical-stage biotechnology company, announced today that the company entered into a license agreement with Wincal Biopharm ("Wincal"), a wholly owned US subsidiary of PharmAbcine, so that Wincal can expand the c...
2020-06-04 00:00
1481
New Small Cell Lung Cancer Drug Accepted for TGA Evaluation Under Project Orbis
Key Highlights * TGA has granted provisional designation for new drug Lurbinectedin based on encouraging Phase 2 results and high unmet medical need * A marketing application has now been accepted by the TGA under provisional evaluation pathway * Lurbinectedin has received priority review u...
2020-06-03 14:30
1423
Firmenich Appoints Boet Brinkgreve as President Ingredients
GENEVA, June 2, 2020 /PRNewswire/ -- In order to strengthen Firmenich industry leadership in ingredients and drive a new era of excellence, Firmenich, has appointed Boet Brinkgreve to President of Ingredients, effectiveJune 1st, 2020. Boet will continue to report directly to Firmenich CEO,Gilbert...
2020-06-02 23:41
1841
Innovent Biologics Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Relapsed or Refractory Extranodal NK/T-Cell Lymphoma (Nasal Type)
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic and other major diseases, announced ...
2020-06-01 07:30
1788
Innovent Biologics and Lilly Jointly Announced the Long-Term Follow-Up Results of TYVYT® (Sintilimab Injection) in the Treatment of Patients with Relapsed/Refractory Classic Hodgkin's Lymphoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the research results of TY...
2020-06-01 07:30
1865
Innovent Biologics and Lilly Jointly Announced the Pivotal Clinical Study Results of TYVYT® (Sintilimab Injection) in the Second-Line Treatment of Patients with Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
SUZHOU, China, May 31, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines, jointly announced with Eli Lilly and Company (Lilly) (NYSE: LLY) the results of TYVYT® (sin...
2020-06-01 07:30
2578
(ASCO2020) Ascentage Pharma Presents Latest Clinical Data of Apoptosis Targeting Drug Candidates, Showing Promising Clinical Effects with Combination Therapies
SUZHOU, China and ROCKVILLE, Md., May 31, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a globally focused, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that the company presented fo...
2020-05-31 20:00
2215
I-Mab Announces Upcoming Participation at June Conferences
SHANGHAI and GAITHERSBURG, Md., May 29, 2020 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel or highly differentiated biologics to treat diseases with significant unmet medical ...
2020-05-29 20:00
6123
Seaweed Extract Offers Hope for Influenza A
CAMBRIDGE, Australia, May 28, 2020 /PRNewswire/ -- Australian scientists have revealed that a natural compound found in seaweed may reduce the effects of severe cases of Influenza A. Fucoidan is a highly bioactive compound found naturally in brown seaweed and well known for its diverse therapeu...
2020-05-28 15:30
1139
IntegriCulture Inc. Closes Series A Fundraising Round Led by Beyond Next Ventures at JPY800 Million
TOKYO, May 28, 2020 /PRNewswire/ -- IntegriCulture Inc. has completed a Series A fundraising round ofJPY800 million (USD7.4 million) backed by Beyond Next Ventures, NH Foods, AgFunder and other investors. The cumulative amount raised stands aboutJPY1.1 billion (USD10.2 million). (Logo: https://...
2020-05-28 13:00
2095
Week's Top Stories
Most Reposted
HS HYOSUNG Unveils New CI and Vision, Embracing "Star" and "Tree" Symbolism
[Picked up by 313 media titles]
2024-09-11 20:27povo2.0, Japan's favourite digital telco, achieves highest user engagement and customer satisfaction rates with Circles' SaaS technology
[Picked up by 301 media titles]
2024-09-06 10:00VinCSS, A Vietnamese Startup, Becomes the World's First Company to Secure FIDO Device Onboarding (FDO) Certificates
[Picked up by 298 media titles]
2024-09-11 15:20
UOB makes strong return to GBP covered bond market with GBP750m 3-year issuance
[Picked up by 276 media titles]
2024-09-06 12:02Chairman Cho Develops Vietnam as Key Base for Sustainable Management
[Picked up by 264 media titles]
2024-09-11 19:29
Most Read
UOB makes strong return to GBP covered bond market with GBP750m 3-year issuance
2024-09-06 12:02
11649
Vieworks Unveils Digital Pathology Scanner LUCEON at ECP 2024
2024-09-06 22:00
5163
UGREEN Introduces New Accessories to Elevate the iPhone 16 Series Experience
2024-09-06 20:18
4908
